1. Home
  2. TCRX

as 06-21-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Founded: 2018 Country:
United States
United States
Employees: N/A City: WALTHAM
Market Cap: 443.0M IPO Year: 2021
Target Price: $11.40 AVG Volume (30 days): 204.0K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.18 EPS Growth: N/A
52 Week Low/High: $1.93 - $9.69 Next Earning Date: 08-08-2024
Revenue: $14,812,000 Revenue Growth: -14.47%
Revenue Growth (this year): -61.94% Revenue Growth (next year): -58.01%

TCRX Daily Stock ML Predictions

Stock Insider Trading Activity of TScan Therapeutics Inc. (TCRX)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
BARBERICH TIMOTHY J TCRX Director Dec 18 '23 Buy $4.89 28,830 $140,880.68 66,710 SEC Form 4
BARBERICH TIMOTHY J TCRX Director Dec 18 '23 Buy $4.97 317 $1,575.01 67,027 SEC Form 4
Klencke Barbara TCRX Director Dec 14 '23 Buy $5.08 5,000 $25,400.00 30,000 SEC Form 4

Share on Social Networks: